Predictive Technology Group (Predictive Technology Group) Cash And Cash Equivalents : $0.15 Mil (As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group Cash And Cash Equivalents?

Predictive Technology Group's quarterly cash and cash equivalents declined from Sep. 2020 ($1.27 Mil) to Dec. 2020 ($0.13 Mil) but then increased from Dec. 2020 ($0.13 Mil) to Mar. 2021 ($0.15 Mil).

Predictive Technology Group's annual cash and cash equivalents increased from Jun. 2018 ($1.21 Mil) to Jun. 2019 ($1.62 Mil) but then declined from Jun. 2019 ($1.62 Mil) to Jun. 2020 ($0.33 Mil).

Predictive Technology Group Cash And Cash Equivalents Historical Data

The historical data trend for Predictive Technology Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group Cash And Cash Equivalents Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.01

0.97

1.21

1.62

0.33

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.21	0.33	1.27	0.13	0.15

Predictive Technology Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Predictive Technology Group (OTCPK:PRED) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Predictive Technology Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.